Literature DB >> 26348996

A Splicing Reporter Tuned to Non-AG Acceptor Sites Reveals that Luteolin Enhances the Recognition of Non-canonical Acceptor Sites.

Masanori Chiba1, Hiroyoshi Ariga2, Hiroshi Maita2.   

Abstract

Removal of an intron requires precise recognition of the splice donor and acceptor sites located at the 5' and 3' termini of introns. Although the roles of these sequences differ, mutations in both sites easily block normal splicing and produce an aberrant mRNA. For example, many splice-site mutations occur in patients with inherited diseases. Several approaches have been evaluated to restore expression of a functional protein; however, because of the strict requirement for an AG dinucleotide at the 3' terminus of a U2-type intron, no method is available to correct splicing at a mutated sequence. To identify compounds that allow splicing at the non-AG acceptor site, in the present study we constructed a reporter gene with a modified polypyrimidine tract. However, the modified polypyrimidine tract mediated splicing at adjacent non-canonical acceptor sites, including the original mutated site. Further, we show that certain flavones such as luteolin and apigenin enhanced aberrant splicing at the non-canonical acceptor site of the reporter gene. These results suggest that the reporter gene and luteolin may be useful for further screening to identify molecules that correct aberrant splicing caused by a disease-associated splice acceptor site mutation.
© 2015 John Wiley & Sons A/S.

Entities:  

Keywords:  3′ splice site; fidelity; luteolin; pre-mRNA splicing; reporter assay

Mesh:

Substances:

Year:  2015        PMID: 26348996     DOI: 10.1111/cbdd.12656

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  5 in total

1.  Novel homozygous nonsense mutation of MLIP and compensatory alternative splicing.

Authors:  Jean Mezreani; Sébastien Audet; Florence Martin; Jade Charbonneau; Valérie Triassi; Eric Bareke; Annie Laplante; Jason Karamchandani; Rami Massie; Colin H Chalk; Erin O'Ferrall; Martine Tétreault
Journal:  NPJ Genom Med       Date:  2022-06-07       Impact factor: 6.083

Review 2.  Hinokiflavone and Related C-O-C-Type Biflavonoids as Anti-cancer Compounds: Properties and Mechanism of Action.

Authors:  Jean-François Goossens; Laurence Goossens; Christian Bailly
Journal:  Nat Prod Bioprospect       Date:  2021-02-03

3.  Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis.

Authors:  Oliver H Voss; Daniel Arango; Justin C Tossey; Miguel A Villalona Calero; Andrea I Doseff
Journal:  Cell Death Dis       Date:  2021-03-17       Impact factor: 8.469

4.  Towards Splicing Therapy for Lysosomal Storage Disorders: Methylxanthines and Luteolin Ameliorate Splicing Defects in Aspartylglucosaminuria and Classic Late Infantile Neuronal Ceroid Lipofuscinosis.

Authors:  Antje Banning; Ritva Tikkanen
Journal:  Cells       Date:  2021-10-20       Impact factor: 7.666

5.  Characterisation of the biflavonoid hinokiflavone as a pre-mRNA splicing modulator that inhibits SENP.

Authors:  Andrea Pawellek; Ursula Ryder; Triin Tammsalu; Lewis J King; Helmi Kreinin; Tony Ly; Ronald T Hay; Richard C Hartley; Angus I Lamond
Journal:  Elife       Date:  2017-09-08       Impact factor: 8.140

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.